Dioxadet and Cisplatin Anti-Tumor Activity Increase in Hyperthermic Intraperitoneal Chemoperfusion on Advanced Ovarian Carcinoma Model

The aim of the investigation was to study the antitumor activity of Dioxadet and Cisplatin in hyperthermic intraperitoneal chemoperfusion (HIPEC) on a rat model of peritoneal carcinomatosis with ascitic ovarian tumor.

Materials and Methods. 103 female Wistar rats were transfected ovarian carcinoma intraperitoneally, 1·10⁷ tumor cells per an animal being injected. After tumor transfection the animals were randomized into 6 groups: group 1 (n=19) — control (0.5 ml normal saline, intraperitoneally); group 2 (n=14) — hyperthermic intraperitoneal perfusion with normal saline (HIPEP); group 3 (n=12) — Cisplatin in normal saline, 4 mg/kg intraperitoneally; group 4 (n=14) — HIPEC with Cisplatin, 20 mg/kg; group 5 (n=19) — Dioxadet in normal saline, 1.5 mg/kg intraperitoneally; group 6 (n=13) — HIPEC with Dioxadet, 15 mg/kg. Antitumor effects were assessed by extended life-span of the animals.

Results. Compared with control, HIPEP with normal saline increased the median survival of rats 2.5 times as much (p=0.008), intraperitoneal injection of Cisplatin and Dioxadet — by 2.2 (p=0.007) and 3.1 times (p=0.001), respectively, HIPEC with Cisplatin and Dioxadet — by 2.8 (p=0.002) and 5.5 times (p<0.001), respectively.

Conclusion. Hyperthermia itself has an antitumor effect on ovarian tumor growth in rats comparable to the effect of intraperitoneal administration of cytostatic agents. The administration of Cisplatin and Dioxadet in HIPEC significantly increases their antitumor activity, HIPEC with Dioxadet having the maximum effect.

1. Wust P., Hildebrant B., Sreenivasa G., et al. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002; 3(8): 487–497, http://dx.doi.org/10.1016/S1470-2045(02)00818-5.
2. Witkamp A.J., de Bree E., Van Goethem R., Zoetmulder F.A. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 2001; 27(6): 365–374, http://dx.doi.org/10.1053/ctrv.2001.0232.
3. Bettaieb A., Wrzal P.K., Averill-Bates D.A. Hyperthermia: Cancer treatment and beyond. In: Cancer treatment — conventional and innovative approaches. Edited by L. Range. InTech; 2013,http://dx.doi.org/10.5772/55795.
4. Current cancer treatment — novel beyond conventional approaches. Edited by Ö. Özdemir. InTech; 2011, http://dx.doi.org/10.5772/897.
5. Sugarbaker P.H. Overview of peritoneal carcinomatosis. Cancerologia 2008; 3: 119–124.
6. Ceelen W.P., Peeters M., Houtmeyers P., et al. Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis. Ann Surg Oncol 2008; 15(2): 535–541, c10.1245/s10434-007-9648-5.
7. Roviello F., Caruso S., Marrelli D., et al. Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: state of the art and future developments. Surg Oncol 2011; 20(1): e38–e54, http://dx.doi.org/10.1016/j.suronc.2010.09.002.
8. Bespalov V.G., Beljaeva O.A., Panchenko A.V., et al. Antitumor activity of dioxadet compared with cisplatin activity in ascitic ovarian tumor rat model. Voprosy onkologii 2011; 57(6): 770–774.
9. Bespalov V.G., Beljaeva O.A., Kireeva G.S., et al. Antitumor effect of dioxadet in intraperitoneal chemoperfusion treatment for advanced ovarian cancer in experimental setting. Voprosy onkologii 2014; 60(2): 72–78.
10. Ahmed K., Zaidi S.F. Treating cancer with heat: hyperthermia as promising strategy to enhance apoptosis. J Pak Med Assoc 2013; 63(4): 504–508.
11. Hegyi G., Szigeti G.P., Szász A. Hyperthermia versus oncothermia: cellular effects in complementary cancer therapy. Evid Based Complement Alternat Med 2013, article ID 672873, http://dx.doi.org/10.1155/2013/672873.
12. Smet L.De, Ceelen W., Remon J.P., Vervaet C. Optimization of drug delivery systems for intraperitoneal therapy to extend the residence time of the chemotherapeutic agent. The Scientific World Journal 2013(2013), article ID 720858, http://dx.doi.org/10.1155/2013/720858.
13. Roberts J.J., Thomson A.J. The mechanism of action of antitumor platinum compounds. Prog Nucleic Acid Res Mol Biol 1979; 22: 71–133.
14. Hasovits C., Clarke S. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics. Clin Pharmacokinet 2012; 51(4): 203–224, http://dx.doi.org/10.2165/11598890-000000000-00000.

Bespalov V.G., Belyaeva О.А., Kireeva G.S., Senchik К.Y., Stukov А.N., Belyaev А.М. Dioxadet and Cisplatin Anti-Tumor Activity Increase in Hyperthermic Intraperitoneal Chemoperfusion on Advanced Ovarian Carcinoma Model. Sovremennye tehnologii v medicine 2014; 6(4): 48